Top

Published in:

01-01-2011 | Letter to the Editor

Flow cytometric analysis of de novo acute myeloid leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Authors: Hideaki Ohta, Shotaro Iwamoto, Nobutaka Kiyokawa, Masahito Tsurusawa, Takao Deguchi, Kozo Takase, Junichiro Fujimoto, Keizo Horibe, Yoshihiro Komada

Published in: International Journal of Hematology | Issue 1/2011

Excerpt

Immunophenotypic analysis has become a powerful tool for the correct identification of leukemic cell lineage. Our study evaluates the diagnostic utility of flow cytometric immunophenotyping of pediatric AML. We retrospectively collected data of immunophenotype from 375 cases of de novo AML studied from 1997 to 2007 at central laboratory institutions of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG): Department of Pediatrics and Developmental Science, Mie University Graduate School of Medicine; Department of Pediatrics, Osaka University Graduate School of Medicine; Center for Clinical Research, National Center for Child Health and Development; and Department of Pediatrics, Aichi Medical University. The diagnosis of AML was made according to the French-American-British (FAB) classification based on morphology and enzyme cytochemical analysis as follows: M0 (acute myeloid leukemia without differentiation, n = 11), M1 (acute myelocytic leukemia with little differentiation, n = 41), M2 (acute myelocytic leukemia with differentiation, n = 113), M4 (acute myelomonocytic leukemia, n = 47), M5 (acute monocytic leukemia, n = 54), M6 (acute erythroleukemia, n = 6), and M7 (acute megakaryoblastic leukemia, n = 61). …

Bene MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol. 2001;113:737–45.CrossRefPubMed

Behm FG. Diagnosis of childhood acute myeloid leukemia. Clin Lab Med. 1999;19:187–237. vii.PubMed

Kotylo PK, Seo IS, Smith FO, Heerema NA, Fineberg NS, Miller K, et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). Am J Clin Pathol. 2000;113:193–200.CrossRefPubMed

Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995;86:3097–108.PubMed

Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsky MA, Johnson LR, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med. 2003;127:42–8.PubMed

Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol. 1992;149:2110–3.PubMed

Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.CrossRefPubMed

Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470–7.PubMed

Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr, Kalwinsky DK, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992;80:3182–8.PubMed

10.

Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243:59–75.CrossRefPubMed

Title: Flow cytometric analysis of de novo acute myeloid leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group
Authors: Hideaki Ohta
Shotaro Iwamoto
Nobutaka Kiyokawa
Masahito Tsurusawa
Takao Deguchi
Kozo Takase
Junichiro Fujimoto
Keizo Horibe
Yoshihiro Komada
Publication date: 01-01-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 1/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0754-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis

Concurrent development of “Burkitt-like” lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin

Repeated donor lymphocyte infusions overcome a myeloid sarcoma of the stomach resulting from a relapse of acute myeloid leukemia after allogeneic cell transplantation in long-term survival of more than 10 years

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

The molecular basis of iron overload disorders and iron-linked anemias

Telomeres and prognosis in patients with chronic lymphocytic leukaemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer